蛋白激酶抑制剂的进步:从发现到临床应用
Salem Baldi1,2, Nanbiao Long1, Shu Ma1
1Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang 422000, China.
Research (Washington, D.C.)
|June 23, 2025
概括
蛋白激酶抑制剂 (PKI) 对于治疗癌症等疾病至关重要. 研究重点是开发更具体的抑制剂,以提高治疗效率和减少副作用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 蛋白激酶调节细胞信号,是治疗疾病,特别是癌症的关键标.
- 蛋白激酶抑制剂 (PKIs) 是现代药物开发的核心,正在进行新的化学支架的研究.
- 开发异型选择性抑制剂对于精确的治疗向和最大限度地减少非向效应至关重要.
研究的目的:
- 审查最近蛋白质激酶抑制剂 (PKI) 治疗方面的进展.
- 突出PKI在癌症之外不断扩大的治疗应用.
- 讨论PKI开发和临床应用的未来方向和挑战.
主要方法:
- 关于蛋白质激酶抑制剂研究和开发近期进展的文献综述.
- 分析临床试验数据和新兴治疗策略.
- 探索整合人工智能和基因编辑技术的新方法.
主要成果:
- 在PKI治疗方面取得了重大进展,扩大了对炎症和神经退行性疾病的应用.
- 开发多功能和异型选择性抑制剂支架对于提高疗效和降低耐药性至关重要.
- 临床案例研究说明了PKI治疗在不断发展的领域中的挑战和机遇.
结论:
- 未来的PKI研究必须通过机理学理解和新的策略优先考虑抑制剂的特异性.
- 组合疗法和克服耐药性是改善临床结果的关键.
- 整合人工智能和CRISPR-Cas9等先进技术对下一代PKI开发具有前景.
相关概念视频
Protein Kinases and Phosphatases
13.5K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.5K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Protein-protein Interfaces
13.7K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


